Searchable abstracts of presentations at key conferences in endocrinology

ea0077p118 | Thyroid | SFEBES2021

Cost-effectiveness analysis of liothyronine for the management of treatment unresponsive hypothyroidism based on latest evidence

Heald Adrian , Skiadas Konstantinos , Fitzsimmons Deborah , Anderson Pippa , Hughes Dyfrig

Introduction: Between 5-10% of patients with hypothyroidism treated with levothyroxine (T4) continue to experience profound symptoms, despite achieving free T4/thyroid stimulating hormone concentrations within reference range. Liothyronine is sometimes added to levothyroxine, but its use is controversial due to uncertainties in clinical/cost effectiveness.Methods: An economic model was developed to estimate the incremental cost per quality-adjusted life ...